About Xbiome
Xbiome is a Healthcare company based in Shenzhen (China) founded in 2017. AI-enabled bioinformatics platform for microbiome-based drug discovery is developed. Xbiome has raised $107.5 million across 5 funding rounds from investors including Primavera Capital Group, Gaorong Capital and Legend Capital. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Xbiome was founded in 2017 in Shenzhen, China, within the biotechnology sector. An AI-enabled bioinformatics platform is utilized by the company to identify drugs based on the intestinal microbiome. Fecal microbiota transplantation (FMT) technology is employed for drug development targeting multiple diseases. Microbiota from healthy donors stool is extracted through established methods and transplanted into patients for therapeutic purposes across various conditions.
- Headquarters Shenzhen, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xbiome.com
- Social LinkedIn
- Total Equity Funding$107.5M (USD)
in 5 rounds
- Latest Funding Round$100M (USD), Series B
Dec 2021
- InvestorsPrimavera Capital Group
& 9 more
Funding Insights of Xbiome
Xbiome has successfully raised a total of $107.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $107.5M
- Total Rounds 5
- Last Round Series B — $100M
- First Round $7.5M
(Aug 2018)
- Investors Count 10
All 5 funding rounds of Xbiome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $100M | Series B | – | Gaorong Capital | |
| Dec 2020 | Series B | – | Primavera, Gaorong Capital | ||
| Nov 2019 | Series B | – | Legend Capital | ||
| Jun 2019 | Series A | – | – | ||
| Aug 2018 | $7.5M | Series A | – | Zhen Fund |
10 investors in total: 9 institutional and 1 angel.
Investors in Xbiome
Xbiome has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Primavera Capital Group, Gaorong Capital and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early and growth-stage TMT startups are funded in China. | gaorongvc.com | Beijing, China | ||
Venture Capital firm focused on multiple sectors | legendcapital.com.cn | Haidian, China | ||
Tech investments are made stage-agnostically in China and the US. | sky9capital.com | Shanghai, China | ||
A venture capital firm focused on technology and innovation investments. | 5ycap.com | Shanghai, China | ||
Private equity investments in China are managed by Primavera. | 2010 | primavera-capital.com | Beijing, China | |
Multi sector investment focused VC fund making early to growth stage investments | hikecapital.com | Chaoyang, China | ||
Tech & Offline focused Seed stage VC Firm investing primarily in Asia and the US | zhenfund.com | Beijing, China | ||
| tiantu.com.cn | ||||
HL Hexin Li | unknown_a8fe5a67cd724723a |
Investor details for Xbiome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xbiome
13 people are tracked at Xbiome (6 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Shuang-Wei Hu | Senior AI Director | Leadership |
Han Hu | CTO | Leadership |
Yan Tan | Co-founder and CEO | Leadership |
Gao Ting | CMC director | Leadership |
Shulin Wang | Chief Medical Science Advisor | Leadership |
Xiaochen Yin | Director Of Bioinformatics | Leadership |
Yulong Zhang | Senior Research Scientist | Team |
Fangshi Dai | 公共关系经理 / Public Relations Manager | Team |
宁 朱 | Senior Manager | Team |
Chengsheng Zhu | Team Lead; Senior Bioinformatics Scientist II | Team |
Xiaomin Xu | Sr Bioinformatics Scientist | Team |
Yi Cai | Bioinformatics Scientist | Team |
Michael Quintin | Bioinformatics Scientist | Team |
Complete people profiles for Xbiome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xbiome
3 dated milestones of Xbiome across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Xbiome is founded.
- Funding First funding round of $7.5M.
- Funding Latest funding round, Series B, of $100.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xbiome
Complete news archive for Xbiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xbiome
Xbiome was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Xbiome is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Xbiome is a funded company, having raised a total of $107.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Aug 2018.
Xbiome was founded in 2017 in Shenzhen, China, within the biotechnology sector. An AI-enabled bioinformatics platform is utilized by the company to identify drugs based on the intestinal microbiome. Fecal microbiota transplantation (FMT) technology is employed for drug development targeting multiple diseases. Microbiota from healthy donors stool is extracted through established methods and transplanted into patients for therapeutic purposes across various conditions.
Xbiome has 10 investors. Key investors include Primavera Capital Group, Gaorong Capital, Legend Capital, Sky9 Capital, and 5Y Capital.